Vifor Pharma Ag Stock Net Income
Vifor Pharma AG fundamentals help investors to digest information that contributes to Vifor Pharma's financial success or failures. It also enables traders to predict the movement of Vifor Pink Sheet. The fundamental analysis module provides a way to measure Vifor Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vifor Pharma pink sheet.
Vifor |
Vifor Pharma AG Company Net Income Analysis
Vifor Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Vifor Pharma Net Income | 146.6 M |
Most of Vifor Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vifor Pharma AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Vifor Pharma AG reported net income of 146.6 M. This is 57.04% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 74.32% higher than that of the company.
Vifor Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vifor Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Vifor Pharma could also be used in its relative valuation, which is a method of valuing Vifor Pharma by comparing valuation metrics of similar companies.Vifor Pharma is currently under evaluation in net income category among its peers.
Vifor Fundamentals
| Return On Equity | 6.65 | |||
| Return On Asset | 4.6 | |||
| Profit Margin | 7.97 % | |||
| Operating Margin | 20.94 % | |||
| Current Valuation | 11.98 B | |||
| Shares Outstanding | 64.86 M | |||
| Shares Owned By Insiders | 0.06 % | |||
| Shares Owned By Institutions | 26.05 % | |||
| Price To Earning | 29.90 X | |||
| Price To Book | 3.29 X | |||
| Price To Sales | 7.97 X | |||
| Revenue | 1.81 B | |||
| Gross Profit | 1.14 B | |||
| EBITDA | 551.5 M | |||
| Net Income | 146.6 M | |||
| Cash And Equivalents | 993.6 M | |||
| Cash Per Share | 15.31 X | |||
| Total Debt | 587.5 M | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 1.91 X | |||
| Book Value Per Share | 55.04 X | |||
| Cash Flow From Operations | 527.4 M | |||
| Earnings Per Share | 6.06 X | |||
| Number Of Employees | 2.2 K | |||
| Beta | 1.37 | |||
| Market Capitalization | 14.45 B | |||
| Total Asset | 3.66 B | |||
| Retained Earnings | 2.01 B | |||
| Working Capital | 567 M | |||
| Current Asset | 1.29 B | |||
| Current Liabilities | 726 M | |||
| Z Score | 14.4 | |||
| Last Dividend Paid | 2.05 |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Vifor Pink Sheet
If you are still planning to invest in Vifor Pharma AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vifor Pharma's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |